Basel, 2 September 2022 - Today Roche (SIX: RO, ROG; OTCQX: RHHBY) inaugurated its new office high-rise, Building 2. Thanks to innovative construction techniques and a pioneering energy concept, it is one of the world's most sustainable high-rises. Roche has invested 550 million Swiss francs in the 205-metre high building, which accommodates 3,200 modern workplaces.
Roche CEO Severin Schwan: “Building 2 is another highly visible sign of Roche's commitment to Basel - the city where Roche was founded over 125 years ago. The building has been designed as a place for dialogue and cooperation, one of the key prerequisites for creativity and innovation. It is a further milestone in the development of our site, creating a modern and highly attractive setting for our head quarter."
Thanks to Building 2, all the employees who have been working at a variety of locations across Basel can be brought together at the heart of the Roche site. The excellent infrastructure at Building 2 encompasses a diverse range of workplaces facilitating different forms of working, from teamwork to highly concentrated working or hybrid working styles.
The continued development of the site is going to plan: the new research & development center is due to open in autumn 2024. Roche is investing 1.2 billion Swiss francs in this project. The development plan for the redesign of the southern section of the Roche site is also being driven forward in close cooperation with the authorities.
Building 2 in brief
Photos and videos of Building 2 can also be found on our website www.roche.ch in the media section.
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
Hans Trees, PhD Phone: +41 61 687 41 47 | Nathalie Altermatt Phone: +41 61 687 43 05 |
Karsten Kleine Phone: +41 61 682 28 31 | Nina Mählitz Phone: +41 79 327 54 74 |
Dr. Barbara von Schnurbein Phone: +41 61 687 89 67 | Sileia Urech Phone: +41 79 935 81 48 |
Attachment
get the latest news and updates to your inbox.